Abstract
Microglia activation is the brain's major immune response to amyloid plaques in Alzheimer's disease (AD). Both cerebrospinal fluid (CSF) levels of soluble TREM2 (sTREM2), a biomarker of microglia activation, and microglia PET are increased in AD;however, whether an increase in these biomarkers is associated with reduced amyloid-beta (A beta) accumulation remains unclear. To address this question, we pursued a two-pronged translational approach. Firstly, in non-demented and demented individuals, we tested CSF sTREM2 at baseline to predict (i) amyloid PET changes over similar to 2 years and (ii) tau PET cross-sectionally assessed in a subset of patients. We found higher CSF sTREM2 associated with attenuated amyloid PET increase and lower tau PET. Secondly, in theApp(NL-G-F)mouse model of amyloidosis, we studied baseline(18)F-GE180 microglia PET and longitudinal amyloid PET to test the microglia vs. A beta association, without any confounding co-pathologies often present in AD patients. Higher microglia PET at age 5 months was associated with a slower amyloid PET increase between ages 5-to-10 months. In conclusion, higher microglia activation as determined by CSF sTREM2 or microglia PET shows protective effects on subsequent amyloid accumulation.
Dokumententyp: | Zeitschriftenartikel |
---|---|
Fakultät: | Medizin |
Themengebiete: | 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit |
ISSN: | 1757-4676 |
Sprache: | Englisch |
Dokumenten ID: | 84829 |
Datum der Veröffentlichung auf Open Access LMU: | 25. Jan. 2022, 09:11 |
Letzte Änderungen: | 25. Jan. 2022, 09:11 |